Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Hepatitis B Virus Gene C1653T Polymorphism Mutation and Hepatocellular Carcinoma Risk: an Updated Meta-analysis

  • Shi, Hua-Ping (Zhejiang University Medical College) ;
  • Zhang, Jun (Laboratory Department, Sir Run Run Show Hospital of Zhejiang University Medical College) ;
  • Shang, Xue-Chai (Central Laboratory, Hang Zhou Red Cross Hospital) ;
  • Xie, Xin-You (Laboratory Department, Sir Run Run Show Hospital of Zhejiang University Medical College)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Although there have been many studies investigating possible associations between the C1653T mutation and risk of HCC, the results have been inconsistent. We conducted searches of the published literature in Pubmed and Embase databases up to January 2013. Seventeen studies with a total of 1,085 HCC cases and 1,365 healthy controls were retrieved. We found a significant association between the C1653T mutation and HCC risk (OR = 2.01, 95%CI= 1.49-2.70). In the subgroup analysis by ethnicity, a significant association was also found in Asians (OR = 2.07, 95%CI= 1.71-2.51). In subgroup analysis by HBV genotype, B and C were linked with development of HCC (B:OR = 2.21, 95%CI= 1.13-4.34; C:OR = 2.26, 95%CI= 1.61-3.16). However, no significant association was found between the C1653T mutation and HCC risk in HBeAg positive cases. In conclusion, this meta-analysis suggests that the C1653T mutation may be associated with susceptibility to HCC.

Keywords

References

  1. Brechot C (2004). Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology, 127, S56-61. https://doi.org/10.1053/j.gastro.2004.09.016
  2. Chan HL, Hui AY, Wong ML, et al (2004).Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-98. https://doi.org/10.1136/gut.2003.033324
  3. Cho EY, Choi CS, Cho JH, et al (2011).Association between Hepatitis B Virus X Gene Mutations and Clinical Status in Patients with Chronic Hepatitis B Infection. Gut Liver, 5, 70-76. https://doi.org/10.5009/gnl.2011.5.1.70
  4. Choi CS, Cho EY, Park R, et al (2009). X gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinoma. J Med Virol, 81, 1721-5. https://doi.org/10.1002/jmv.21591
  5. Chu CM,(2002).Precore stop mutant in anti-HBe-positive phases of chronic hepatitis B virus infection. Am J Gastroenterol,97, 2138-9.
  6. Cong YS, Yao YL, Yang WM, et al (1997). The hepatitis B virus X-associated protein, XAP3, is a protein kinase Cbinding protein. J Biol Chem, 272, 16482-9. https://doi.org/10.1074/jbc.272.26.16482
  7. Fang ZL, Sabin CA, Dong BQ, et al (2008). HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol, 103, 2254-62. https://doi.org/10.1111/j.1572-0241.2008.01974.x
  8. Ferlay J, Shin HR, Bray F, et al (2010).Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-17. https://doi.org/10.1002/ijc.25516
  9. Guo X, Jin Y, Qian G, et al (2008). Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol, 49, 718-25. https://doi.org/10.1016/j.jhep.2008.06.026
  10. Ja KK, Hye YC, Jung ML, et al (2009). Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol, 81, 1002-8. https://doi.org/10.1002/jmv.21501
  11. Jang JW, Chun JY, Park YM, et al (2012). Mutational complex genotype of the hepatitis B virus X/precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci, 103, 296-304. https://doi.org/10.1111/j.1349-7006.2011.02170.x
  12. Kumar V, Jayasuryan N, Kumar R (1996). A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. ProcNatl Acad Sci USA, 93, 5647-52. https://doi.org/10.1073/pnas.93.11.5647
  13. Lee H, Kim HT, Yun Y, et al (1998). Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression. J Biol Chem, 273, 19786-91. https://doi.org/10.1074/jbc.273.31.19786
  14. Liu S, Zhang H, Gu C, et al (2009). Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst, 101, 1066-82. https://doi.org/10.1093/jnci/djp180
  15. Parkin DM, Bray FI, Devesa S, et al (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 37, S4-66.
  16. Qu LS, Liu TT, Jin F, et al (2011). Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: A nested case-control study in China. Hepatol Res, 41, 54-63. https://doi.org/10.1111/j.1872-034X.2010.00732.x
  17. Sakamoto T, Tanaka Y, Orito E, et al (2006). Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol, 87, 1873-82. https://doi.org/10.1099/vir.0.81714-0
  18. Sakurai M, Sugauchi F, Tsai N, et al (2004). Genotype and phylogenetic characterization of hepatitis B virus among multi-ethnic cohort in Hawaii. World J Gastroenterol, 10, 2218-22.
  19. Sherman M (2010). Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis, 30, 3-16. https://doi.org/10.1055/s-0030-1247128
  20. Shinkai N, Tanaka Y, Ito K, et al (2007). Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol, 45, 3191-7. https://doi.org/10.1128/JCM.00411-07
  21. Sirma H, Giannini C, Poussin K, et al (1999). Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene, 18, 4848-9. https://doi.org/10.1038/sj.onc.1202867
  22. Stemler M, Weimer T, Tu ZX, et al (1990). Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol, 64, 2802-9.
  23. Tanaka Y, Mukaide M, Orito E, et al (2006). Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol, 45, 646-53. https://doi.org/10.1016/j.jhep.2006.06.018
  24. Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, et al (2010). A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int, 4, 577-84. https://doi.org/10.1007/s12072-010-9197-z
  25. Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458. https://doi.org/10.1186/1471-2407-11-458
  26. Wang Z, Tanaka Y, Huang Y, et al (2007). Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol, 45, 1491-6. https://doi.org/10.1128/JCM.02157-06
  27. Welschinger R, Kew MC, Viana R, et al (2010). T1653 mutation in the enhancer II region of the hepatitis B virus genome in southern African Blacks with hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 22, 541-5. https://doi.org/10.1097/MEG.0b013e3283344991
  28. Yuan J, Zhou B, Tanaka Y, et al (2007). Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. J Clin Virol, 39, 87-93. https://doi.org/10.1016/j.jcv.2007.03.005
  29. Yuen MF, Tanaka Y, Shinhai N, et al (2008). Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C,specific mutations of enhancer II/core. Gut, 57, 98-102.
  30. Zhang KY, Imazeki F, Fukai K, et al (2007). Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci, 98, 1921-9. https://doi.org/10.1111/j.1349-7006.2007.00609.x
  31. Zhu Y, Jin Y, Guo X, et al (2010). Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev, 19, 2623-30. https://doi.org/10.1158/1055-9965.EPI-10-0469

Cited by

  1. Hepatitis B Virus Gene Mutations and Hepatocarcinogenesis vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4509
  2. Meta-analysis of the correlation between the rs17401966 polymorphism in kinesin family member 1B and susceptibility to hepatitis B virus related hepatocellular carcinoma vol.23, pp.2, 2017, https://doi.org/10.3350/cmh.2016.0083